BioCity Heralds New Phase of Growth with CFO Appointment
News Nov 04, 2015
BioCity has appointed Paul Oliver as chief financial officer to drive the next stage of growth across its four sites in England and Scotland.
Paul Oliver joins BioCity, having previously been chief financial officer of the FTSE 250 pharmaceutical company Vectura Group plc where, among other significant achievements, he helped oversee a major €130m international acquisition and a £52m equity placing on the London Stock Exchange.
On joining BioCity, Paul said: "I'm excited to be joining such a unique organization. BioCity is exemplary in the way it supports, nurtures and invests in early stage biotech companies and I look forward to helping BioCity continue the excellent progress it has made to date."
Speaking about Paul Oliver's appointment, BioCity CEO Glenn Crocker said: "We are delighted to welcome Paul to BioCity at this exciting period in the Company's growth. Paul is an established and well-regarded CFO who has gained considerable relevant experience within the UK pharmaceutical industry. His strong financial control, market knowledge and transaction experience will be a considerable asset for BioCity.”
2nd AI Pharma Innovation: Drug Discovery 2019 Summit
Feb 27 - Feb 28, 2019
5th International Congress on Epigenetics & Chromatin
Aug 22 - Aug 23, 2019
14th World Congress on Medicinal Chemistry and Drug Design
Jun 10 - Jun 11, 2019
International Conference on e-Health and Healthcare Innovations
May 08 - May 09, 2019